Regiane Penaforte Santos

Ms. Regiane Penaforte Santos

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024
Verified
Journal Article
Open access
PDF file
PDPedro Henrique Villar Delfino
Pedro Henrique Villar Delfino
RSRegiane Penaforte Santos
Regiane Penaforte Santos
PCPaulo Pereira Christo
Paulo Pereira Christo
JNJosé Augusto Nogueira-Machado
José Augusto Nogueira-Machado
CVCaroline Maria Oliveira Volpe
Caroline Maria Oliveira Volpe
Aim: Neuroinflammation is a characteristic of multiple sclerosis (MS). Resveratrol (RSV) has potent antioxidant properties and has emerged as a promising therapeutic agent for various inflammatory diseases. This study investigated the effects of RSV on inflammatory responses via reactive oxygen species (ROS) production and leukocyte cytokine secretion in patients with MS and healthy controls. Methods: The effects of RSV on ROS production in resting and stimulated granulocytes (in the presence of opsonized particles) were assessed using luminol-dependent chemiluminescence. The cytokines interleukin (IL)-10, IL-1β, IL-6, and high mobility group box 1 (HMGB1) in the supernatant of peripheral blood mononuclear cells (PBMNCs) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: RSV significantly downregulated ROS production in resting and stimulated granulocytes in patients with MS and healthy controls. In the control group, RSV reduced IL-6 levels by 49% in the PBMNC supernatant, whereas IL-6 levels remained unchanged in the MS group. Interestingly, higher levels of IL-10 were detected in PBMNC supernatants from patients with MS than in controls. No significant changes were observed in IL-1β and HMGB1 levels in the PBMNC supernatant. Conclusions: Controlling ROS production is a key target for treating inflammatory diseases. Our findings suggest that RSV can effectively modulate ROS production in MS, highlighting its potential as a promising adjunct therapy for controlling oxidative innate immune responses in MS.

21 March 2025 in Journal of Molecular and Clinical Medicine
Verified
Journal Article
Open access
LALuciana Ferreira Antunes
Luciana Ferreira Antunes
RSRegiane Penaforte Santos
Regiane Penaforte Santos
JCJúlia Vieira Carvalho
Júlia Vieira Carvalho
PCPaulo Pereira Christo
Paulo Pereira Christo
PDPedro Henrique Villar Delfino
Pedro Henrique Villar Delfino
CVCaroline Maria Oliveira Volpe
Caroline Maria Oliveira Volpe
Background: Multiple sclerosis (MS) is a neurological disorder that is directly linked to inflammation in the central nervous system (CNS). The activation of toll-like receptors (TLRs) exacerbates neuroinflammation by increasing the production of reactive oxygen species (ROS) and proinflammatory cytokines. Edaravone (EDV) has been proposed as a potential therapy for CNS diseases because of its free radical scavenging and anti-inflammatory properties. This study investigated the effects of EDV on the inflammatory response in TLR4-stimulated peripheral blood mononuclear cells (PBMNCs) from MS patients and a healthy control group. Methods: The impact of EDV on ROS production in lipopolysaccharide (LPS)-stimulated PBMNCs was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) reduction and luminol-dependent chemiluminescence assays. The interleukin (IL)-6 concentration in the PBMNC supernatants was measured using enzyme-linked immunosorbent assay (ELISA). Results: The results showed that ROS production in PBMNCs stimulated using LPS (a TLR4 activator) was significantly inhibited (p < 0.05) by EDV in the MS patients and control group. Additionally, EDV significantly reduced IL-6 secretion in TLR4-stimulated PBMNCs in these groups (p < 0.05). No significant differences were observed between the groups. Conclusion: Our findings suggest that EDV may serve as an adjunctive therapy for MS by reducing ROS and IL-6 production in TLR4-stimulated PBMNCs in MS patients, highlighting its potential in modulating neuroinflammation and oxidative stress.

3 November 2026 in Receptors
Verified
Journal Article
Open access
PDF file
RSRegiane Penaforte Santos
Regiane Penaforte Santos
JCJúlia Vieira Carvalho
Júlia Vieira Carvalho
ACAmanda Medeiros Frota Cruz
Amanda Medeiros Frota Cruz
LALuciana Ferreira Antunes
Luciana Ferreira Antunes
JJJuliana Silveira Gontijo Rigueira Juliana
Juliana Silveira Gontijo Rigueira Juliana
CVCaroline Maria de Oliveira Volpe
Caroline Maria de Oliveira Volpe
Background/Objectives: Obesity is characterized by chronic low-grade inflammation and oxidative stress, mediated in part by Toll-like receptor (TLR)-associated pathways. Bariatric surgery improves clinical and metabolic parameters, but its effects on TLR-associated reactive oxygen species (ROS) responses in immune cells remain unclear. This study aimed to investigate ROS production following TLR2- and TLR4-associated stimulation in granulocytes from women with obesity before and after bariatric surgery, compared with age-matched non-obese controls. Methods: ROS production was evaluated using a luminol-dependent chemiluminescence assay in granulocytes isolated from women with obesity before (PRE, n = 12) and after (POST, n = 12) bariatric surgery, as well as from age-matched non-obese controls (n = 12). ROS production was assessed under basal conditions and following stimulation with lipopolysaccharide (LPS, a TLR4 agonist) or zymosan (ZY, a TLR2-associated stimulus). Clinical, anthropometric, and biochemical parameters were assessed, and their associations with ROS production were analyzed. Results: Bariatric surgery was associated with significant improvements in clinical and metabolic parameters, although mean BMI in the POST group remained within the obesity range. Granulocytes from the PRE group exhibited increased basal ROS production and enhanced responses following both LPS and ZY stimulation. In the POST group, basal ROS production and the response following ZY stimulation were comparable to those observed in controls, whereas LPS-associated ROS production remained elevated. Correlation analyses showed positive associations between anthropometric and biochemical parameters and ROS production in both PRE and POST groups, with body weight and BMI remaining positively associated with basal and LPS-associated ROS production after surgery. Conclusions: Bariatric surgery was associated with substantial clinical and metabolic improvement but did not completely restore innate immune redox homeostasis. The persistence of TLR4-driven ROS production suggests that some alterations in innate immune redox balance may persist after surgery despite metabolic improvement.